Food Allergy

The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.

In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.

In this video, part 4 of a 5-part series, panelists discuss gaps in clinician education regarding food allergies and anaphylaxis.

In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

This February 2025 month in review covers key updates in allergy, including advancements in immunotherapy and new insights on food allergy desensitization.

A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.

Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.

HCPLive spoke with Cohen about how patients with a peanut allergy responded to oral immunotherapy with autoclaved peanuts.

HCPLive spoke with Warren at AAAAI 2025 about a pilot study showing allergen-free food subscriptions reduced healthcare use but lacked significance.

Stallergenes Greer announced that Palforzia is now available for children under 4 years old with a peanut allergy, which follows the extended indication approval in July 2024.

A study at AAAAI 2025 found that dupilumab led to a 73.5% reduction in IgE levels at 24 months.

Five years after peanut oral immunotherapy, children showed lower allergen-specific IgE and greater IgG4 levels than placebo, indicating sustained immune tolerance.

ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.

A study found no negative effect of food allergies on school performance, with better grades in severe cases, but results were nonsignificant in sibling analyses.

This systematic review and meta-analysis highlighted several key findings on use of probiotics as a treatment of pediatric patients with allergies to food.

The investigators assessed the proportion of households that chose to eliminate allergens by specific allergies to foods and to evaluate related psychosocial functioning among families.

In this analysis, baseline peanut sIgE was shown to be a stronger predictor of remission after peanut OIT than age at the beginning of immunotherapy treatment.

The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.